Abnova | Cash Flow

Fiscal year is January-December. All values TWD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
88,495.00
77,396.00
55,447.00
57,029.00
72,874.00
37,106
Depreciation, Depletion & Amortization
39,327.00
37,654.00
36,187.00
35,792.00
36,495.00
40,926
Other Funds
-
-
-
27,862.00
-
33,423
Funds from Operations
107,738.00
105,362.00
75,691.00
70,085.00
94,745.00
44,609
Changes in Working Capital
2,636.00
11,087.00
2,810.00
2,255.00
26,872.00
45,295
Net Operating Cash Flow
110,374.00
94,275.00
72,881.00
72,340.00
67,873.00
89,904
Capital Expenditures
34,106.00
19,663.00
168,292.00
78,278.00
88,454.00
Sale of Fixed Assets & Businesses
240.00
180.00
521.00
352.00
1,949.00
Purchase/Sale of Investments
40.00
2,323.00
195,667.00
107,900.00
-
Net Investing Cash Flow
34,346.00
17,414.00
366,393.00
30,451.00
18,315.00
Cash Dividends Paid - Total
71,456.00
65,502.00
59,547.00
11,145.00
23,516.00
Issuance/Reduction of Debt, Net
596.00
95.00
1,285.00
396.00
344.00
Net Financing Cash Flow
72,052.00
65,597.00
106,671.00
39,403.00
23,860.00
Net Change in Cash
3,976.00
11,264.00
399,752.00
59,970.00
24,916.00
Free Cash Flow
91,779.00
85,477.00
80,663.00
12,753.00
13,214.00
Other Sources
-
133.00
37.00
697.00
68,572.00
Change in Capital Stock
-
-
48,409.00
-
-
Exchange Rate Effect
-
-
431.00
3,418.00
782.00
Other Uses
440.00
387.00
2,992.00
220.00
382.00

About Abnova

View Profile
Address
108 Jhouzih Street
Taipei TP 114
Taiwan
Employees -
Website http://www.abnova.com.tw
Updated 07/08/2019
Abnova Taiwan Corp. is engaged in researching, developing, manufacturing and selling antibodies. It also supplies medicines and human genes albumen. Its products include antibodies for virus, microbial, neuroscience and others.